Literature DB >> 36180571

Ubiquitin-specific protease 3 facilitates cell proliferation by deubiquitinating pyruvate kinase L/R in gallbladder cancer.

Ruo-Peng Liang1, Xiao-Xue Zhang2, Jie Zhao1, Rong-Tao Zhu1, Wei-Jie Wang1, Qin-Wei Lu1, Yu-Ling Sun3.   

Abstract

Ubiquitin-specific protease 3 (USP3), a kind of cysteine protease, is a crucial family member of deubiquitinating enzymes. USP3 is aberrantly expressed in several tumors, which may contribute to cancer progression. However, the role of USP3 in gallbladder cancer (GBC) is still unknown. In the current study, we detected the expression of USP3 in GBC tissues, measured its contribution to the cell proliferation in GBC progression, and further studied the underlying mechanism of USP3 in GBC through pyruvate kinase L/R (PKLR; a kind of glycolytic enzyme). We found that the expression of USP3 in GBC tissues were higher than that of adjacent tissues, and the protein levels of USP3 and PKLR were positively correlated. Additionally, overexpressed USP3 significantly promoted cell proliferation in vitro and tumor growth in vivo, while the silencing of USP3 inhibited proliferation and tumor growth. Glycolysis in GBC cells ws promoted by the USP3 overexpression and inhibited bye USP3 downregulation. Moreover, the loss of USP3 promoted the ubiquitination and weakened the stability of PKLR. Results of the rescue assay confirmed that PKLR knockdown suppressed USP3-induced oncogenic activity in USP3 overexpressed GBC cells. These findings imply that USP3 is an essential positive regulator in GBC progression, and USP3-PKLR plays a vital role in the progression and metabolism of GBC.
© 2022. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.

Entities:  

Year:  2022        PMID: 36180571     DOI: 10.1038/s41374-022-00836-1

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.502


  39 in total

Review 1.  Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.

Authors:  Anne M Horgan; Eitan Amir; Thomas Walter; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

Review 2.  Management of gallbladder cancer in India.

Authors:  M Rajgopal Acharya; Shraddha Patkar; Amir Parray; Mahesh Goel
Journal:  Chin Clin Oncol       Date:  2019-07-30

3.  Gallbladder Cancer.

Authors:  Ioana Baiu; Brendan Visser
Journal:  JAMA       Date:  2018-09-25       Impact factor: 56.272

Review 4.  Carcinoma of the gallbladder.

Authors:  Sanjeev Misra; Arun Chaturvedi; Naresh C Misra; Indra D Sharma
Journal:  Lancet Oncol       Date:  2003-03       Impact factor: 41.316

Review 5.  Gallbladder cancer.

Authors:  Jessica A Wernberg; Dustin D Lucarelli
Journal:  Surg Clin North Am       Date:  2014-02-18       Impact factor: 2.741

6.  Epigenetic Biomarkers in Gallbladder Cancer.

Authors:  Pramod K Tiwari
Journal:  Trends Cancer       Date:  2020-04-11

7.  USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors.

Authors:  Jun Cui; Yanxia Song; Yinyin Li; Qingyuan Zhu; Peng Tan; Yunfei Qin; Helen Y Wang; Rong-Fu Wang
Journal:  Cell Res       Date:  2013-12-24       Impact factor: 25.617

8.  Smad Ubiquitination Regulatory Factor 1 (Smurf1) Promotes Thyroid Cancer Cell Proliferation and Migration via Ubiquitin-Dependent Degradation of Kisspeptin-1.

Authors:  Chunyan Yan; Haiying Su; Xiyuan Song; Huiling Cao; Lingling Kong; Wen Cui
Journal:  Cell Physiol Biochem       Date:  2018-09-21

Review 9.  Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.

Authors:  Aarti Sharma; Kiran Lata Sharma; Annapurna Gupta; Alka Yadav; Ashok Kumar
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

10.  Ubiquitin-specific protease 3 overexpression promotes gastric carcinogenesis and is predictive of poor patient prognosis.

Authors:  Chia-Lang Fang; Chih-Chan Lin; Han-Kun Chen; You-Cheng Hseu; Shih-Ting Hung; Ding-Ping Sun; Yih-Huei Uen; Kai-Yuan Lin
Journal:  Cancer Sci       Date:  2018-09-21       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.